| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Henry F Bradfor. The use of foetal human brain tissue as brain implants: phenotype manipulation by genetic manipulation and biochemical induction. The Keio journal of medicine. vol 51. issue 3. 2002-10-29. PMID:12371646. |
one is to convert embryonic cerebral cortex in human embryos into dopaminergic tissue which is stable, and which will secrete dopamine in vivo once implanted. |
2002-10-29 |
2023-08-12 |
human |
| Henry F Bradfor. The use of foetal human brain tissue as brain implants: phenotype manipulation by genetic manipulation and biochemical induction. The Keio journal of medicine. vol 51. issue 3. 2002-10-29. PMID:12371646. |
these cells can be expanded in number many-fold before treatment to direct their development into stable dopaminergic neurones in large numbers (70%), which synthesise and release dopamine. |
2002-10-29 |
2023-08-12 |
human |
| Z-H Feng, T-G Wang, D-D Li, P Fung, B C Wilson, B Liu, Syed F Ali, R Langenbach, J-S Hon. Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl1, 2, 3, 6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra. Neuroscience letters. vol 329. issue 3. 2002-10-28. PMID:12183047. |
these results indicate that loss of cox-2 activity reduces mptp-induced damage to the dopaminergic neurons of the snc, but does not alter the levels of dopamine and its metabolites in the striatum. |
2002-10-28 |
2023-08-12 |
mouse |
| Nadine Kabbani, Laszlo Negyessy, Ridwan Lin, Patricia Goldman-Rakic, Robert Levenso. Interaction with neuronal calcium sensor NCS-1 mediates desensitization of the D2 dopamine receptor. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 22. issue 19. 2002-10-24. PMID:12351722. |
ncs-1-d2 receptor interaction may serve to couple dopamine and calcium signaling pathways, thereby providing a critical component in the regulation of dopaminergic signaling in normal and diseased brain. |
2002-10-24 |
2023-08-12 |
human |
| György Szekeres, László Pávics, Zoltán Jank. [Investigation of the dopamine dysregulation hypothesis of schizophrenia with neuroimaging techniques]. Ideggyogyaszati szemle. vol 55. issue 7-8. 2002-10-23. PMID:12201230. |
in accordance with the modified dopamine hypothesis, the cognitive deficit and negative symptoms are related to the hypoactivity of the dorsolateral prefrontal cortex while the acute phases of the disease associates with hyperactivity of the ventral striatal elements of the dopaminergic system. |
2002-10-23 |
2023-08-12 |
Not clear |
| Hengyi Xiao, Yoko Hirata, Ken-Ichi Isobe, Kazutoshi Kiuch. Glial cell line-derived neurotrophic factor up-regulates the expression of tyrosine hydroxylase gene in human neuroblastoma cell lines. Journal of neurochemistry. vol 82. issue 4. 2002-10-18. PMID:12358785. |
the role of glial cell line-derived neurotrophic factor (gdnf) in the survival of dopaminergic neurons has been well documented, but its effect on dopamine biosynthesis remains to be elucidated. |
2002-10-18 |
2023-08-12 |
human |
| G Gille, W D Rausch, S T Hung, R Moldzio, A Ngyuen, B Janetzky, A Engfer, H Reichman. Protection of dopaminergic neurons in primary culture by lisuride. Journal of neural transmission (Vienna, Austria : 1996). vol 109. issue 2. 2002-10-16. PMID:12075855. |
in primary mouse mesencephalic cultures we show that the dopamine d1/d2 receptor agonist lisuride, in a concentration range of 0.001-1 microm, enhances the survival of dopaminergic neurons, protects against toxicity induced by l-dopa or 1-methyl-4-phenylpyridinium ion (mpp+) and stimulates 3h-dopamine uptake. |
2002-10-16 |
2023-08-12 |
mouse |
| Shinya Kagawa, Takayuki Nakano, Osamu Inoue, Tsunehiko Nishimur. Effect of glutamatergic systems on in vivo binding of [(125)I]beta-CIT in the brain of a rat model of Parkinson's disease. Synapse (New York, N.Y.). vol 46. issue 1. 2002-10-16. PMID:12211097. |
these results indicate that the glutamatergic system significantly affects the function of dopamine transporters in the degenerated dopaminergic neurons in parkinson's disease. |
2002-10-16 |
2023-08-12 |
rat |
| Rita M Condren, Neda Sharifi, Jogin H Thakor. A preliminary study of dopamine-mediated prolactin inhibition in generalised social phobia. Psychiatry research. vol 111. issue 1. 2002-10-10. PMID:12140123. |
the aim of this study was to examine central dopaminergic function in patients with generalised social phobia using the prolactin response to quinagolide, a dopamine d2 receptor agonist, and to compare responses with those of normal controls. |
2002-10-10 |
2023-08-12 |
human |
| Françoise Rougé-Pont, Willy Mayo, Michela Marinelli, Mireille Gingras, Michel Le Moal, Pier Vincenzo Piazz. The neurosteroid allopregnanolone increases dopamine release and dopaminergic response to morphine in the rat nucleus accumbens. The European journal of neuroscience. vol 16. issue 1. 2002-10-09. PMID:12153544. |
the neurosteroid allopregnanolone increases dopamine release and dopaminergic response to morphine in the rat nucleus accumbens. |
2002-10-09 |
2023-08-12 |
rat |
| Sanjeev Choudhary, Geetu Raheja, Vandana Gupta, Kiran Dip Gil. Possible involvement of dopaminergic neurotransmitter system in dichlorvos induced delayed neurotoxicity. Journal of biochemistry, molecular biology, and biophysics : JBMBB : the official journal of the Federation of Asian and Oceanian Biochemists and Molecular Biologists (FAOBMB). vol 6. issue 1. 2002-10-09. PMID:12186780. |
single subcutaneous dose of dichlorvos (200 mg/kg body weight) resulted in marked changes in the dopaminergic neurotransmitter system in terms of increased levels of both dopamine and norepinephrine along with significant increase in the activity of both the catecholamine synthesizing enzymes, tyrosine hydroxylase (th) and dopamine-beta-hydroxylase. |
2002-10-09 |
2023-08-12 |
rat |
| Istvan Sziráki, Henry Sershen, Audrey Hashim, Abel Lajth. Receptors in the ventral tegmental area mediating nicotine-induced dopamine release in the nucleus accumbens. Neurochemical research. vol 27. issue 3. 2002-10-04. PMID:11958525. |
nicotine-induced increase of accumbal dopamine release was inhibited by intrategmental nicotinic (mecamylamine), muscarinic (atropine), dopaminergic (d1: sch 23390, d2: eticlopride), and nmda glutamatergic (mk 801) and gabab (saclofen) antagonists, but not by ampa-kainate (cnqx, gyki52466) antagonists under our experimental circumstances. |
2002-10-04 |
2023-08-12 |
Not clear |
| Jan A Pechenik, Wei Li, David E Cochran. Timing is everything: the effects of putative dopamine antagonists on metamorphosis vary with larval age and experimental duration in the prosobranch gastropod Crepidula fornicata. The Biological bulletin. vol 202. issue 2. 2002-10-04. PMID:11971809. |
overall, our results would then suggest that exposing larvae of c. fornicata to excess k(+) leads to a shutdown of nitric oxide synthesis via a dopaminergic pathway, a pathway that can be blocked by some dopamine antagonists. |
2002-10-04 |
2023-08-12 |
Not clear |
| K S Raevskii, R R Gainetdinov, E A Budygin, P Mannisto, M Wightma. Dopaminergic transmission in the rat striatum in vivo in conditions of pharmacological modulation. Neuroscience and behavioral physiology. vol 32. issue 2. 2002-10-01. PMID:11942697. |
the effects of pharmacological modulation of striatal dopaminergic neurotransmission were studied in freely mobile rats by intracerebral microdialysis and hplc to assay dopamine and dopamine metabolite levels and the rate of dopamine synthesis, in combination with observations of stereotypical behavior. |
2002-10-01 |
2023-08-12 |
rat |
| K Ray Chaudhuri, Suvankar Pal, Christine Brefel-Courbo. 'Sleep attacks' or 'unintended sleep episodes' occur with dopamine agonists: is this a class effect? Drug safety. vol 25. issue 7. 2002-09-27. PMID:12093305. |
a series of case reports suggested that this phenomenon may not be exclusive to the non-ergot dopamine agonists such as pramipexole or ropinirole and indeed may occur with most dopaminergic agents. |
2002-09-27 |
2023-08-12 |
Not clear |
| K Ray Chaudhuri, Suvankar Pal, Christine Brefel-Courbo. 'Sleep attacks' or 'unintended sleep episodes' occur with dopamine agonists: is this a class effect? Drug safety. vol 25. issue 7. 2002-09-27. PMID:12093305. |
recent evidence suggest that a 'sleepiness' or 'hypoactivity' reaction to dopaminergic therapy may be related to underlying dopamine deficiency of pd rather than a drug effect. |
2002-09-27 |
2023-08-12 |
Not clear |
| K Ray Chaudhuri, Suvankar Pal, Christine Brefel-Courbo. 'Sleep attacks' or 'unintended sleep episodes' occur with dopamine agonists: is this a class effect? Drug safety. vol 25. issue 7. 2002-09-27. PMID:12093305. |
those with reported 'sleep attacks' or 'unintended sleep episodes' and excessive daytime sleepiness while taking dopamine agonists or dopaminergic agents such as levodopa should have a review of their medication, should not be driving a car on their own and some may merit formal sleep architecture studies. |
2002-09-27 |
2023-08-12 |
Not clear |
| Alessandro Zuddas, Cristina Mancosu, Vanessa Lilliu, Giuseppe Sorrentino, Umberto di Porzio, Carlo Cianchett. 6R-Tetrahydrobiopterin induces dopamine synthesis in a human neuroblastoma cell line, LA-N-1. A cellular model of DOPA-responsive dystonia. Brain research. vol 943. issue 2. 2002-09-27. PMID:12101048. |
in these patients the nigrostriatal dopaminergic neurons normally express th and the cellular machinery for the dopamine uptake. |
2002-09-27 |
2023-08-12 |
human |
| M C Porter, L S Appiah-Kubf, K R Chaudhur. Treatment of Parkinson's disease and restless legs syndrome with cabergoline, a long-acting dopamine agonist. International journal of clinical practice. vol 56. issue 6. 2002-09-27. PMID:12166546. |
dopamine agonists have diverse chemical and physical properties that can directly stimulate the dopamine receptors, unlike levodopa which undergoes presynaptic breakdown to dopamine before dopaminergic effects in parkinson's disease (pd). |
2002-09-27 |
2023-08-12 |
Not clear |
| M C Porter, L S Appiah-Kubf, K R Chaudhur. Treatment of Parkinson's disease and restless legs syndrome with cabergoline, a long-acting dopamine agonist. International journal of clinical practice. vol 56. issue 6. 2002-09-27. PMID:12166546. |
in theory, therapy with cabergoline provides striatal intrasynaptic dopamine replacement of pd in a physiological manner because of its long half-life and the resultant sustained rather than pulsatile dopaminergic stimulation. |
2002-09-27 |
2023-08-12 |
Not clear |